Hemodiafiltration Versus Hemodialysis and Survival in Patients With ESRD: The French Renal Epidemiology and Information Network (REIN) Registry

详细信息    查看全文

• 作者：Lucile Mercadal ; MD ; PhD¹ ; ² ; ³ ; ⁴ ; ^{lucile.mercadal@aphp.fr" class="auth_mail" title="E-mail the corresponding author} ; Jeanna-Eve Franck ; MSc² ; Marie Metzger ; PhD² ; ³ ; ⁴ ; Pablo Urena Torres ; MD ; PhD⁵ ; Franç ; ois de Cornelissen ; MD⁶ ; Sté ; phane Edet ; MD⁷ ; Clé ; mence Bé ; chade ; MD⁸ ; Cé ; cile Vigneau ; MD⁹ ; Tilman Dr&uuml ; eke ; MD² ; ³ ; ⁴ ; Christian Jacquelinet ; MD ; PhD² ; ³ ; ⁴ ; ¹⁰ ; Bé ; né ; dicte Stengel ; MD ; PhD² ; ³ ; ⁴ ; on behalf of the REIN Registry^&lowast ;
• 关键词：Hemodialysis (HD) ; hemodiafiltration (HDF) ; treatment modality ; registry-based study ; epidemiology ; dialysis ; mortality ; cardiovascular mortality ; survival ; end-stage renal disease (ESRD)
• 刊名：American Journal of Kidney Diseases
• 出版年：2016
• 出版时间：August 2016
• 年：2016
• 卷：68
• 期：2
• 页码：247-255
• 全文大小：570 K

文摘

Recent randomized trials report that mortality is lower with high-convection-volume hemodiafiltration (HDF) than with hemodialysis (HD).

bsSec_2">Study Design

bspara0015">We used data from the French national Renal Epidemiology and Information Network (REIN) registry to investigate trends in HDF use and its relationship with mortality in the total population of incident dialysis patients.

bsSec_3">Setting & Participants

bspara0020">The study included those who initiated HD therapy from January 1, 2008, through December 31, 2011, and were dialyzed for more than 3 months; follow-up extended to the end of 2012.

bsSec_4">Factor

bspara0025">HDF use at the patient and facility level.

bsSec_5">Outcomes

bspara0030">All-cause and cardiovascular mortality, using Cox models to estimate HRs of HDF as time-dependent covariate at the patient level, with age as time scale and fully adjusted for comorbid conditions and laboratory data at baseline, catheter use, and facility type as time-dependent covariates. Analyses completed by Cox models for HRs of the facility-level exposure to HDF updated yearly.

bsSec_6">Results

bspara0035">Of 28,407 HD patients, 5,526 used HDF for a median of 1.2 (IQR, 0.9-1.9) years; 2,254 of them used HDF exclusively. HRs for all-cause and cardiovascular mortality associated with HDF use were 0.84 (95% CI, 0.77-0.91) and 0.73 (95% CI, 0.61-0.88), respectively. In patients treated exclusively with HDF, these HRs were 0.77 (95% CI, 0.67-0.87) and 0.66 (95% CI, 0.50-0.86). At the facility level, increasing the percentage of patients using HDF from 0% to 100% was associated with HRs for all-cause and cardiovascular mortality of 0.87 (95% CI, 0.77-0.99) and 0.72 (95% CI, 0.54-0.96), respectively.

bsSec_7">Limitations

bspara0040">Observational study.

bsSec_8">Conclusions

bspara0045">Whether analyzed as a patient- or facility-level predictor, HDF treatment was associated with better survival.